Advertise with us
[December 11, 2005]
Nanotechnology device maker retains KGMC Group, LLC to launch Nano-JETA technology platform
(Genomics & Genetics Weekly)
2005 DEC 9 - (NewsRx.com) -- Acrongenomics, Inc., (AGNM) has retained KGMC Group, LLC, of Frankfort, Illinois, to introduce its Nano-JETA technology platform to the world market.
KGMC Group LLC will work with Acrongenomics to complete formal validations of the advanced Nano-JETA platform, secure publications of this breakthrough technology in respected medical and scientific journals and identify ideal partners to commercialize the technology.
"Following a year of thorough study, our scientists and board of directors have confirmed that Acrongenomics' know-how in nanotechnology has resulted in compelling breakthroughs, significantly impacting our battle with various diseases such as cancer. We are convinced that Nano-JETA technology platform can accelerate and enhance the commonly used Real Time PCR amplification process, so that it is rendered 100% accurate in detecting genetic diseases such as cancer," said KGMC group president Bill Kanatas.
"Neo-EpCAM cancer detection assay is the first application utilizing the Nano-JETA technology. More so exciting is that the process takes less than 2 minutes. Because it is fast, inexpensive, easy to administer, non-invasive, accurate, specific and uses existing equipment, we are convinced that the technology will assist physicians in detecting genetic diseases quickly, accurately and early enough to potentially save lives and avoid much cost and anguish. Now confident in the technology, we will assist Acrongenomics in securing a partner to further develop and market such technology," said Kanatas.
Acrongenomics has successfully conducted laboratory tests and clinical trials for the cancer detection and quantification process. The technology has been applied to major Molecular Diagnostics techniques such as Polymerase Chain Reaction (PCR) and Real-Time PCR producing outstanding results in terms of sensitivity, reproducibility, specificity and speed with the use of conventional equipment.
This article was prepared by Genomics & Genetics Weekly editors from staff and other reports. Copyright 2005, Genomics & Genetics Weekly via NewsRx.com.
Back To NFVZone's Homepage